Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as trivalent vaccine candidate
VXB-251 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| VXB-251, low dose | EXPERIMENTAL | - |
| VXB-251, medium dose | EXPERIMENTAL | - |
| VXB-251, high dose | EXPERIMENTAL | - |
| VXB-241 | EXPERIMENTAL | - |
| VXB-213 | EXPERIMENTAL | - |
| VXB-221 | EXPERIMENTAL | - |
| VXB-232 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| trivalent (RSV/hMPV/PIV3) vaccine candidate | BIOLOGICAL | VXB-251 low dose, single, IM injection. |
| bivalent (RSV/hMPV) unlicensed comparator | BIOLOGICAL | VXB-241 medium dose, single, IM injection. |
| monovalent (RSV) unlicensed comparator | BIOLOGICAL | VXB-213 medium dose, single, IM injection. |
| Biological/Vaccine: monovalent (hMPV) unlicensed comparator | BIOLOGICAL | VXB-221 medium dose, single, IM injection. |
| monovalent (PIV3) unlicensed comparator | BIOLOGICAL | VXB-232 medium dose, single, IM injection. |
| Placebo | OTHER | diluent, single, IM injection. |
Inclusion Criteria: 1. Males and females aged 60 to 83 years of age at inclusion. 2. Evidence of signed and dated participant informed consent form (PICF) prior to any study procedure, indicating that the subject has been informed of all pertinent aspects of the study. 3. Willingness and ability to...
VXB-251 is an investigational trivalent vaccine candidate developed by Sanofi that targets three respiratory viruses: respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus 3 (PIV3). It is being studied in older adults to prevent lower respiratory tract disease and is currently in Phase 1 clinical development.
VXB-251 is being developed to prevent lower respiratory tract disease caused by RSV, hMPV, and PIV3 in older adults. The Phase 1 trial enrolls healthy participants aged 60 years and older. It is an investigational vaccine and has not been approved for any indication.
VXB-251 is developed by Sanofi, which trades on the New York Stock Exchange under the ticker SNY. Sanofi is the sponsor of the ongoing Phase 1 clinical trial evaluating the vaccine candidate in older adults.
VXB-251 is in Phase 1 clinical development. One Phase 1 trial is active and currently not recruiting, with no completed trials. The study is randomized, double-blind, and placebo-controlled, enrolling 240 participants in Australia.
VXB-251 is being evaluated in a single Phase 1 trial, NCT07295028, titled "Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults." The trial is active but not recruiting, enrolls 240 healthy participants aged 60 and older in Australia, and uses a randomized, double-blind, placebo-controlled design.